{"organizations": [], "uuid": "a9b8621471803e229bcca570a85316839da341ea", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180301.html", "section_title": "Archive News &amp; Video for Thursday, 01 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-nektar-therapeutics-q4-loss-per-sh/brief-nektar-therapeutics-q4-loss-per-share-0-21-idUSASB0C8H5", "country": "US", "domain_rank": 408, "title": "Nektar Therapeutics Q4 Loss Per Share $0.21", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.636, "site_type": "news", "published": "2018-03-02T05:49:00.000+02:00", "replies_count": 0, "uuid": "a9b8621471803e229bcca570a85316839da341ea"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-nektar-therapeutics-q4-loss-per-sh/brief-nektar-therapeutics-q4-loss-per-share-0-21-idUSASB0C8H5", "ord_in_thread": 0, "title": "Nektar Therapeutics Q4 Loss Per Share $0.21", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "nektar therapeutics", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 1 (Reuters) - Nektar Therapeutics:\n* REPORTS FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS\n* Q4 LOSS PER SHARE $0.21 * Q4 REVENUE $95.5 MILLION VERSUS $37.5 MILLION Source text for Eikon:\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-02T05:49:00.000+02:00", "crawled": "2018-03-02T20:01:01.013+02:00", "highlightTitle": ""}